Peripheral T-cell Lymphoma Clinical Trial
Official title:
A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphoma
Verified date | November 2019 |
Source | Celgene |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To determine the maximum tolerated dose of lenalidomide in patients with adult T-cell leukemia-lymphoma (ATL) and peripheral T-cell lymphoma (PTCL) who have previously received therapy for ATL and PTCL
Status | Completed |
Enrollment | 13 |
Est. completion date | December 20, 2013 |
Est. primary completion date | December 1, 2013 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years and older |
Eligibility |
Inclusion Criteria: 1. Subject must understand and voluntarily sign the written informed consent; 2. Aged 20 years or older; 3. Subject have a documented diagnosis of either: - Acute-, lymphoma-, or unfavorable chronic-type ATL or - Peripheral T-cell Lymphomaperipheral (PTCL) 4. Subject have received =1 prior anti-cancer therapy, have achieved stable disease (SD) or better on their immediately prior therapy and have relapsed or progressed at the time of obtaining signed informed consent; 5. Subject have an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 2 at enrollment; Exclusion Criteria: 1. Natural Killer cell lymphoma (NK-cell lymphoma); 2. T-cell leukemia; 3. Cutaneous T-cell lymphoma (CTCL) including; - Mycosis fungoides - Sezary syndrome - CD30-positive lympho-proliferative disorders - Cutaneous gamma/delta T-cell lymphoma 4. Subject have a history of central nervous system (CNS) involvement or present with CNS symptoms, and are diagnosed with CNS lymphoma by cerebrospinal fluid (CSF) cytology examination, head CT scan or brain MRI during the screening; 5. Are pregnant or lactating; 6. Subject have uncontrolled inter-current illness including: - Uncontrolled diabetes mellitus - Chronic congestive heart failure (NYHA Class III or IV) - Unstable angina pectoris, angioplasty, stenting, or myocardial infarction (within 6 months before starting the study drug) - Clinically significant cardiac arrhythmia that is symptomatic or requires treatment, or asymptomatic sustained ventricular tachycardia - Other uncontrolled diseases 7. Exhibit grade 4 neurological disorders; 8. Subject have a history or complication of deep vein thrombosis or pulmonary embolism within 6 months before the start of study treatment; 9. Develop active tuberculous disease, herpes simplex, systemic mycosis, or other active infections requiring systemic administration of antibiotics, antiviral agents, or antifungal drugs; 10. Are tested positive for HBs antigen, anti-HCV antibody, or anti-HIV antibody; 11. Subjects have a history or complication for which the investigator or subinvestigator deems them inappropriate for this study, or have serious diseases or mental illness that is likely to be aggravated by participation in this study; 12. Subjects have a history of allogeneic stem cell transplantation; 13. Subjects have received autologous stem cell transplantation within 12 weeks (84 days) of the start of study treatment; 14. Have previously used lenalidomide; 15. Have a history of desquamating (bullous) rash while taking thalidomide; 16. Have received any investigational drugs (unapproved drugs in Japan) within 4 weeks (28 days) of the start of study medication; 17. Have received chemotherapeutic agents or immunomodulators for the treatment of ATL or PTCL within 4 weeks (28 days) of the start of study treatment; 18. Have received radiotherapy within 4 weeks (28 days) of the start of study treatment; 19. Have a history or complication of another malignant tumor than ATL or PTCL (excluding malignant tumors below), unless the patients have been free of the disease for 5 years or longer; - Cutaneous basal cell carcinoma or squamous cell carcinoma - Cervical carcinoma in situ - An incidental histological finding of prostate carcinoma (TNM stage T1a or T1b) 20. Have had any of the following abnormal measurements at screening performed within 1 week (7 days) prior to the enrollment; - Neutrophil count: < 1,200/µL (1.2 x 109/L) - Platelet count: < 75,000/µL (75 x 109/L) - Serum aspartate aminotransferase/ Serum glutamic oxaloacetic transaminase (AST/SGOT) or Alanine transaminase/Serum Glutamic Pyruvate Transaminase (ALT/SGPT): > 3 times the Upper Limit of Normal (ULN) - Bilirubin level: > 1.5 times of the ULN - Creatinine clearance: < 60 mL/min |
Country | Name | City | State |
---|---|---|---|
Japan | National Kyusyu Cancer Center | Fukuoka | |
Japan | Imamura Bun-in Hospital | Kagoshima | |
Japan | Kumamoto University Hospital | Kumamoto | |
Japan | Nagasaki University Hospital | Nagasaki | |
Japan | Nagoya Daini Red Cross Hospital | Nagoya | |
Japan | National Cancer Center Hospital | Tokyo |
Lead Sponsor | Collaborator |
---|---|
Celgene |
Japan,
Ogura M, Imaizumi Y, Uike N, Asou N, Utsunomiya A, Uchida T, Aoki T, Tsukasaki K, Taguchi J, Choi I, Maruyama D, Nosaka K, Chen N, Midorikawa S, Ohtsu T, Tobinai K. Lenalidomide in relapsed adult T-cell leukaemia-lymphoma or peripheral T-cell lymphoma (ATLL-001): a phase 1, multicentre, dose-escalation study. Lancet Haematol. 2016 Mar;3(3):e107-18. doi: 10.1016/S2352-3026(15)00284-7. Epub 2016 Feb 12. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The safety of lenalidomide evaluated based on the severity of adverse events and their causality | The safety of lenalidomide evaluated based on the severity of adverse events and their causality | Up to 2.5 years | |
Secondary | Response | The response of ATL patient to lenalidomide will be evaluated according to the criteria proposed by the International Consensus Meeting. The response of PTCL will be assessed by the Japan Clinical Oncology Group (JCOG) response criteria that have been established by the Lymphoma Study Group of the JCOG based on criteria of Cheson et al.in the Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas |
Up to 2.5 years | |
Secondary | PK-Time to Maximum Plasma Concentration (Tmax) | PK-Time to Maximum Plasma Concentration (Tmax) | Day 8 of Cycle 1 | |
Secondary | PK-Apparent Total Body Clearance (CL/F) | PK-Apparent Total Body Clearance (CL/F) | Day 8 of Cycle 1 | |
Secondary | PK-Apparent Volume of Distribution (Vz/F) | PK-Apparent Volume of Distribution (Vz/F) | Day 8 of Cycle 1 | |
Secondary | PK-Terminal half-life (T1/2) | PK-Terminal half-life (T1/2) | Day 8 of Cycle 1 | |
Secondary | PK-Area under the Plasma concentration time curve (AUC) | PK-Area under the Plasma concentration time curve (AUC) | Day 8 of Cycle 1 | |
Secondary | Accumulation ratio (Cmax) | Accumulation ratio (Cmax) | Day 8 of Cycle 1 | |
Secondary | Accumulation ratio (AUCt) | Accumulation ratio (AUCt) | Day 8 of Cycle 1 | |
Secondary | PK-Maximum Concentration in Plasma (Cmax) | PK-Maximum Concentration in Plasma (Cmax) | Day 8 of cycle 1 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00038025 -
A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies
|
Phase 2 | |
Recruiting |
NCT02445404 -
Compare Efficacy of CHOP Versus Fractionated ICED in Transplant-eligible Patients With Previously Untreated PTCL
|
Phase 2 | |
Completed |
NCT02168140 -
CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma
|
Phase 1 | |
Terminated |
NCT01644253 -
Phase 1b Safety and Efficacy Study of TRU-016
|
Phase 1 | |
Completed |
NCT01689220 -
A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea
|
Phase 1 | |
Completed |
NCT01435863 -
A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL)
|
Phase 1 | |
Completed |
NCT01427881 -
Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies
|
Phase 2 | |
Terminated |
NCT00441025 -
The Effectiveness of Alemtuzumab Combination With CHOP to Treat Patients Newly Diagnosed With PTCL
|
Phase 2 | |
Completed |
NCT00078858 -
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant
|
Phase 1/Phase 2 | |
Completed |
NCT00003196 -
Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma
|
N/A | |
Active, not recruiting |
NCT04312841 -
Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab
|
Phase 2 | |
Recruiting |
NCT04040491 -
PD-1 Antibody, Chidamide, Lenalidomide and Gemcitabine for Peripheral T-cell Lymphoma
|
Phase 4 | |
Terminated |
NCT01678443 -
Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies
|
Phase 1 | |
Completed |
NCT01588015 -
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
|
Phase 1 | |
Completed |
NCT02264613 -
ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas
|
Phase 1/Phase 2 | |
Completed |
NCT02142530 -
Carfilzomib Plus Belinostat in Relapsed/Refractory NHL
|
Phase 1 | |
Terminated |
NCT01408043 -
Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma
|
N/A | |
Completed |
NCT00131937 -
Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma
|
Phase 2 | |
Completed |
NCT00791947 -
A Nordic Phase II Study of PTCL Based on Dose-intensive Induction and High-dose Consolidation With ASCT
|
Phase 2 | |
Recruiting |
NCT04880746 -
Efficacy and Safety of Cladribine Combined With BEAC Pretreatment Regimen in the Treatment of Peripheral T-cell Lymphoma: a Multicenter Clinical Study
|
Phase 3 |